Nuclea Biotechnologies agrees to research partnership with Stratton VA Medical Center in Albany

Nuclea Biotechnologies agrees to research partnership with Stratton VA Medical Center in Albany
March 12, 2012

Pittsfield, MA -- Biomarker pioneer Nuclea Biotechnologies, Inc. today announced a new research partnership with the Stratton VA Medical Center and Albany Research Institute in Albany, NY.  As part of this new collaboration, Nuclea and Stratton will work together on the analysis of   samples from  patients who have been diagnosed with prostate cancer, or a precancerous or benign prostate condition,  order to determine potential protein and gene characteristics that could  provide valuable information to clinicians for the diagnosis or prognosis of these conditions in similar patients.

"We are very excited about this partnership with Stratton," said Patrick Muraca, president & CEO of Nuclea. "This collaboration will result in a very unique clinical trial where we will be evaluating how Fatty Acid Synthase (FAS) works to diagnose and predict prostate cancer in very specific populations, such as veterans."

"As the population of Vietnam-era veterans continues to age, they will become increasingly at-risk for prostate cancer," Muraca added.  "We are very hopeful that FAS will allow earlier, more accurate diagnosis of patients with this disease, as well as better treatment."

According to the American Cancer Society, there were more than 217,000 cases of prostate cancer reported in the United States in 2010, and more 32,000 related deaths.  Employing its large proprietary biorepository that includes more than 150,000 clinical specimens and an unprecedented amount of clinical data, Nuclea has developed new FAS-based diagnostic tests designed to significantly improve the detection and monitoring of prostate cancer.  Nuclea has filed for pre-market guidance with the FDA for its prostate cancer monitoring diagnostic test showing that FAS levels are predictive of metastatic risk.

Nuclea Biotechnologies, Inc. is headquartered in Pittsfield, Massachusetts. Nuclea has three lines of business, each of which is operated by a separate wholly-owned subsidiary: Nuclea Diagnostic Laboratories ("NDL") which has developed and is commercializing unique diagnostic tests for colon, breast, leukemia, lung and prostate cancer; Nuclea Biomarkers ("NBM") which performs research leading to novel molecular oncology therapeutics and diagnostics for the pharmaceutical and biotechnology industries and performs services by analyzing and testing the efficacy and validating other indications of existing therapeutics utilizing a highly characterized and consented patient database; and Nuclea Biotherapeutics ("NBT") which develops novel therapeutics.

[email protected]

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.